Inactive Instrument

Other languages Organovo Holdings Inc Nyse

Equities

US68620A1043

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 15	Organovo's fatty liver disease drug meets main goal in mid-stage study	RE
Apr. 15	Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Organovo's fatty liver disease drug meets main goal in mid-stage study	Apr. 15
Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	Apr. 15
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08
Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings	Jan. 25
Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results	Dec. 06
Organovo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09
Organovo Holdings, Inc. Highlights FXR314 Combination Therapy Potential and Plan	Nov. 08
Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data	23-08-23
Organovo Holdings, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10
Organovo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-14
Organovo Holdings, Inc. Auditor Raises 'Going Concern' Doubt	23-07-13
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-09
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates	22-11-15
Organovo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-10
Organovo Holdings, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-11
Organovo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-06-10
Organovo Holdings to Proceed With Target Discovery, Validation for Crohn's Disease After Achieving 3D Tissue Model	22-05-17
Organovo Holdings, Inc. Successfully Advances Its First Inflammatory Bowel Disease Model to the Next Step of Target Discovery and Validation for Crohn’s Disease	22-05-17
Organovo Holdings, Inc. Appoints vaidehi Joshi to the Board as Class I Director	22-03-10
Organovo, BICO Reach Patent License Agreement for 3D Bioprinting	22-02-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Organovo Holdings Inc Nyse

Equities

US68620A1043

Other languages

Filters